Amarin Corporation PLC (AMRN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Amarin Corporation PLC (AMRN) has a cash flow conversion efficiency ratio of 0.014x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($6.39 Million) by net assets ($449.41 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see AMRN company net worth for the company's overall valuation and market capitalisation.
Amarin Corporation PLC - Cash Flow Conversion Efficiency Trend (1993–2025)
This chart illustrates how Amarin Corporation PLC's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Amarin Corporation PLC Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Amarin Corporation PLC ranked by their cash flow conversion efficiency. Explore Amarin Corporation PLC cash flow quality index to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Modern Avenue Group Co Ltd
SHE:002656
|
-0.393x |
|
Okins Electronics Co. Ltd
KQ:080580
|
0.113x |
|
Weifu High Tech Group
SHE:200581
|
0.049x |
|
Alussa Energy Acquisition Corp. II
NYSE:ALUB
|
-0.001x |
|
Upstream Bio, Inc.
NASDAQ:UPB
|
-0.131x |
|
Xiangyang BOYA Precision Industrial Equipments Co. Ltd
SHE:300971
|
0.044x |
|
LiveWire Group Inc.
NYSE:LVWR
|
-0.459x |
|
Jiangsu Lanfeng Bio-chemical Co Ltd
SHE:002513
|
-0.330x |
Annual Cash Flow Conversion Efficiency for Amarin Corporation PLC (1993–2025)
The table below shows the annual cash flow conversion efficiency of Amarin Corporation PLC from 1993 to 2025. View Amarin Corporation PLC (AMRN) share price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $459.28 Million | $6.74 Million | 0.015x | +123.01% |
| 2024-12-31 | $486.18 Million | $-31.02 Million | -0.064x | -610.03% |
| 2023-12-31 | $552.10 Million | $6.91 Million | 0.013x | +104.14% |
| 2022-12-31 | $595.33 Million | $-179.98 Million | -0.302x | -203.14% |
| 2021-12-31 | $667.10 Million | $-66.53 Million | -0.100x | -187.78% |
| 2020-12-31 | $627.50 Million | $-21.75 Million | -0.035x | -125.06% |
| 2019-12-31 | $608.26 Million | $-9.37 Million | -0.015x | +97.52% |
| 2018-12-31 | $152.33 Million | $-94.70 Million | -0.622x | -223.25% |
| 2017-12-31 | $-65.10 Million | $-32.84 Million | 0.504x | -93.64% |
| 2016-12-31 | $-9.06 Million | $-71.81 Million | 7.928x | +1108.61% |
| 2015-12-31 | $-129.19 Million | $-84.75 Million | 0.656x | -19.76% |
| 2014-12-31 | $-88.45 Million | $-72.31 Million | 0.818x | -85.46% |
| 2013-12-31 | $-33.86 Million | $-190.34 Million | 5.622x | -81.63% |
| 2012-12-31 | $-4.00 Million | $-122.30 Million | 30.599x | +362.56% |
| 2011-12-31 | $-5.96 Million | $-39.44 Million | 6.615x | +3852.38% |
| 2010-12-31 | $-202.37 Million | $-33.87 Million | 0.167x | +128.94% |
| 2009-12-31 | $48.60 Million | $-28.11 Million | -0.578x | +36.67% |
| 2008-12-31 | $28.90 Million | $-26.39 Million | -0.913x | +16.07% |
| 2007-12-31 | $24.15 Million | $-26.28 Million | -1.088x | -79.72% |
| 2006-12-31 | $37.84 Million | $-22.91 Million | -0.605x | -34.98% |
| 2005-12-31 | $38.58 Million | $-17.31 Million | -0.449x | +30.19% |
| 2004-12-31 | $16.69 Million | $-10.73 Million | -0.643x | -119.89% |
| 2003-12-31 | $-6.35 Million | $-20.50 Million | 3.230x | +459.06% |
| 2002-12-31 | $-6.21 Million | $5.59 Million | -0.900x | -257.77% |
| 2001-12-31 | $29.67 Million | $16.91 Million | 0.570x | +216.06% |
| 2000-12-31 | $31.17 Million | $5.62 Million | 0.180x | +123.07% |
| 1999-12-31 | $12.18 Million | $-9.53 Million | -0.782x | -270.26% |
| 1998-12-31 | $-13.50 Million | $-6.20 Million | 0.459x | +1787.78% |
| 1997-12-31 | $14.70 Million | $-400.00K | -0.027x | +94.80% |
| 1996-12-31 | $23.30 Million | $-12.20 Million | -0.524x | -415.25% |
| 1995-12-31 | $28.90 Million | $4.80 Million | 0.166x | +179.99% |
| 1993-12-31 | $18.30 Million | $-3.80 Million | -0.208x | -- |
About Amarin Corporation PLC
Amarin Corporation plc, a pharmaceutical company, engages in the commercialization and development of therapeutics for the treatment of cardiovascular diseases in the United States, Europe, and internationally. It offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. The compa… Read more